Our History

Qurgen Inc. was established in Michigan, USA.

Qurgen obtained an exclusive, permanent and global intellectual property licensing agreement from Wayne State University.

Qurgen announced the successful completion of its Pre-A round financing of 4 million USD that will be used to accelerate the company’s research and development, with a focus on developing Qurgen’s cell-conversion cancer therapy for a Phase I clinical trial.

Qurgen announced that the Company had successfully completed its Series A financing with 12 million USD that will be mainly used for the FDA IND application and clinical studies of SON-DP, a first-in-human and first-in-class transcription factor anti-cancer protein drug that leads to a breakthrough cell-conversion cancer therapy.

Qurgen received FDA IND approval (IND #152226) for the Phase I clinical trial of SON-DP, a first-in-human and first-in-class transcription factor anti-cancer protein drug that leads to a breakthrough cell-conversion cancer therapy for all solid tumors.

Qurgen’s 30,000 sq. ft. GMP protein drug manufacturing facility was completed and commissioned. 

Qurgen had successfully manufactured two lots of GMP-manufactured SON-DP anti-cancer drugs that met FDA/CDE protein drug quality standard. Both lots of SON-DP will be used in the US and China Phase I clinical trials.

Qurgen had successfully manufactured two lots of GMP-manufactured SON-DP anti-cancer drugs that met FDA/CDE protein drug quality standard. Both lots of SON-DP will be used in the US and China Phase I clinical trials.

Qurgen completed the annual physical examination of five Cynomolgus monkeys.